Home / Stocks / Fortis Healthcare Ltd
FORTIS

Fortis Healthcare Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹809.85

Change

+16.3 (2.05%)

Open

₹791.3

Prev. Close

₹793.55

Day High

₹809.85

Day Low

₹784.0

Volume Analysis

Traded

780,641

Delivered

412,191

Delivery %

52.8%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (22.0%)

Weaknesses (0)

No signal for this stock

Opportunities (1)

  • •Strong 3-year EPS growth (21.0%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹844.31 ₹827.08 ₹818.46 ₹801.23 ₹792.61 ₹775.38 ₹766.76
Fibonacci ₹827.08 ₹817.21 ₹811.1 ₹801.23 ₹791.36 ₹785.25 ₹775.38
Camarilla ₹816.96 ₹814.59 ₹812.22 ₹801.23 ₹807.48 ₹805.11 ₹802.74

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-10.07%

1 Week

+6.56%

1 Month

+11.09%

3 Months

-10.72%

6 Months

-15.68%

1 Year

-13.42%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹207.75

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

9.43%

Net margin 10.72% × asset turnover 0.56x × equity multiplier 1.57x

Company Overview

Sector

Healthcare

Market Cap

₹61,047 Cr

P/E (TTM)

56.9

ROE

11.2%

Book Value

₹139.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Fortis Healthcare Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (14/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (22.0%). FII holding has been falling.

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

85

Valuation

14

Cash Flow

85

Corporate Governance

53

Momentum

33

Institutional Ownership

73

Business Quality

68

Risk & Volatility

60

Liquidity

83

From Screener.in

  • +Company has delivered good profit growth of 64.3% CAGR over last 5 years
  • −Stock is trading at 5.80 times its book value
  • −Company has a low return on equity of 9.87% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of November 6, 2026 investor meet on Q2FY27 results is available online.

Board approved Q2/H1 FY27 unaudited results; standalone revenue ₹519.41 crore, net profit ₹129.91 crore.

Fortis reported Q2 FY27 revenue of INR 2,735 Cr, acquired Suguna Hospital, and signed 400+ bed Delhi agreement.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,770 1,680 1,786 1,859 1,988 1,928 2,007 2,167 2,331 2,265 2,365 2,545 2,735
Expenses + 1,440 1,396 1,405 1,516 1,554 1,553 1,572 1,676 1,775 1,759 1,832 2,008 2,112
Operating Profit 330 284 381 343 435 375 435 491 556 506 532 537 623
OPM % 19.0% 17.0% 21.0% 18.0% 22.0% 19.0% 22.0% 23.0% 24.0% 22.0% 23.0% 21.0% 23.0%
Other Income + 18 19 17 14 -42 47 -29 31 50 -34 -2 28 16
Interest 32 33 35 35 36 45 68 70 75 86 84 80 78
Depreciation 84 87 92 91 95 97 102 101 106 120 122 122 128
Profit before tax 233 183 271 230 261 279 237 351 425 266 324 363 432
Tax % 21.0% 27.0% 25.0% 24.0% 26.0% 9.0% 21.0% 24.0% 23.0% 26.0% 16.0% 25.0% 26.0%
Net Profit + 184 134 203 174 193 254 188 267 329 197 271 273 320
EPS in Rs 2 2 2 2 2 3 2 3 4 3 4 4 4
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 10 8 9 12 12 15 12 17 17 17 18 17 17

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 3,966 4,199 4,574 4,561 4,469 4,632 4,030 5,718 6,298 6,893 7,783 9,128 9,910
Expenses + 3,857 4,106 4,220 4,287 4,238 4,022 3,626 4,649 5,196 5,625 6,195 7,043 7,711
Operating Profit 109 92 354 274 231 610 404 1,069 1,101 1,268 1,588 2,085 2,198
OPM % 2.8% 2.2% 8.0% 6.0% 5.0% 13.0% 10.0% 19.0% 17.0% 18.0% 20.0% 23.0% 22.0%
Other Income + 92 299 649 -689 228 126 95 367 157 64 -11 45 8
Interest 152 133 229 258 337 205 166 147 129 131 184 314 329
Depreciation 235 225 222 239 233 292 291 301 316 342 386 449 492
Profit before tax -185 34 552 -912 -110 239 43 988 814 858 1,007 1,366 1,385
Tax % 2.0% -24.0% 13.0% 2.0% 103.0% 62.0% 230.0% 20.0% 22.0% 25.0% 20.0% 22.0% —
Net Profit + -130 42 479 -934 -224 91 -56 790 633 645 809 1,064 1,062
EPS in Rs -3 0 8 -19 -4 1 -1 7 8 8 10 14 14
Dividend Payout % -1.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 13.0% 13.0% 10.0% 7.0% —
Sales growth 14 6 9 0 -2 4 -13 42 10 9 13 17 18

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 3,585 3,998 4,626 3,543 5,846 5,906 5,365 5,423 6,487 6,908 8,162 9,141 9,723
Borrowings + 1,784 1,513 2,217 1,962 2,010 1,594 1,531 1,255 926 1,155 2,475 3,473 3,164
Other Liabilities + 1,760 1,257 2,227 2,455 2,875 2,781 3,216 4,082 3,921 4,153 1,985 2,465 2,772
Total Liabilities 7,592 7,232 9,588 8,479 11,486 11,036 10,866 11,516 12,089 12,971 13,377 15,833 16,415
Fixed Assets + 4,218 3,642 5,419 4,992 8,477 8,802 8,799 9,416 9,426 9,874 10,424 12,230 12,373
CWIP 228 226 268 226 450 204 165 193 228 542 407 434 495
Investments 1,464 1,452 1,878 1,732 270 175 186 104 210 230 169 243 254
Other Assets + 1,682 1,913 2,023 1,529 2,290 1,856 1,716 1,803 2,225 2,326 2,378 2,926 3,292
Total Assets 7,592 7,232 9,588 8,479 11,486 11,036 10,866 11,516 12,089 12,971 13,377 15,833 16,415
Equity Capital 463 463 518 519 755 755 755 755 755 755 755 755 755

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 24 195 966 493 -179 172 485 865 822 1,100 1,424 1,601
Cash from Investing Activity + 213 122 -1,001 -333 -3,279 63 -131 -501 -372 -889 -780 -1,537
Cash from Financing Activity + -304 -354 259 -672 4,257 -862 -143 -517 -471 -86 -714 164
Net Cash Flow -66 -37 225 -513 799 -627 212 -153 -21 125 -70 228
Free Cash Flow -181 -162 689 437 -261 35 274 750 367 172 591 673
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 131 354 304 187 30 84 108 101 100 104 97 90

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 31.17% → 31.17%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 15.71% 14.44% 13.22% 12.83% 12.02% 11.98% 11.87% 11.79% 11.65% 11.5% 11.4% 11.18%
Promoters 31.17% 31.17% 31.17% 31.17% 31.17% 31.17% 31.17% 31.17% 31.17% 31.17% 31.17% 31.17%
FII 23.72% 23.24% 23.31% 25.26% 26.77% 27.4% 27.18% 27.9% 27.84% 25.98% 25.2% 23.2%
DII 29.42% 31.14% 32.31% 30.73% 30.05% 29.46% 29.79% 29.14% 29.33% 31.35% 32.23% 34.45%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Fortis Healthcare Ltd (this stock) 61,047 56.9 5.81 11.2%
Alkem Laboratories Ltd. 61,875 28.6 4.16 18.9%
Biocon Limited. 58,962 86.5 1.69 1.4%
Aster Dm Quality Care Ltd 63,907 122.0 8.2 11.3%
Gland Pharma Limited 53,710 42.9 5.01 10.7%
Anthem Biosciences Ltd 51,355 81.4 15.65 22.3%
Glenmark Pharmaceuticals 73,937 36.5 6.59 23.6%

Which Mutual Funds Hold Fortis Healthcare Ltd?

Frequently Asked Questions about Fortis Healthcare Ltd

Community Sentiment

What are other investors saying about Fortis Healthcare Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.